Aeterna Zentaris to Present Poster on Oral Prostate Cancer Vaccine Candidate, AEZS-120, at Upcoming International Urology

Aeterna Zentaris to Present Poster on Oral Prostate Cancer Vaccine Candidate,
       AEZS-120, at Upcoming International Urology Conference in Japan

PR Newswire

QUEBEC CITY, Sept. 20, 2012

QUEBEC CITY, Sept. 20, 2012 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ:
AEZS) (TSX:AEZ) (the "Company") today announced that a poster on its oral
prostate cancer vaccine candidate, AEZS-120, will be on display at the
upcoming 32^nd Congress of the Société Internationale d'Urologie which will be
held September 30 through October 4, 2012 at the Fukuoka International
Congress Center in Fukuoka, Japan.

The abstract #839 titled, "Pre-Clinical Proof of Concept and Characterization
of AEZS-120, a Therapeutic Oral Prostate Cancer Vaccine Candidate Based on
Live Recombinant Attenuated Salmonella", J. Fensterle, B. Bergmann, M. Teifel,
J. Engel, T. Rudel, W. Goebel, U. Rapp, underlines the feasibility of an oral
therapeutic vaccination approach against prostate cancer. The safety
pharmacology and toxicology experiments suggest that the profile of AEZS-120
is similar to the approved carrier strain and, therefore, pave the way for
Phase 1 clinical testing.

About AEZS-120

AEZS-120 is a live recombinant oral tumor vaccine candidate based on
Salmonella typhi Ty21a as a carrier strain. Salmonella typhi Ty21a is an
approved oral typhoid vaccine which has been safely applied in more than 350
million doses. The principle of AEZS-120 is based on the recombinant
expression of prostate specific antigen fused to the B subunit of cholera
toxin and a secretion signal in the presence of the Escherichia coli type I
hemolysin secretion system. The proprietary system allows the secretion of the
antigen together with an immunological adjuvant which has been demonstrated to
be required for optimal induction of CD8 T-cell responses by recombinant
Salmonella based bacterial vaccines. The proof-of-concept was already
demonstrated for the mouse homologue of AEZS-120 in a mouse tumor-challenge

In general, by varying the antigen and/or the carrier, this proprietary
platform technology is suitable for virtually any therapeutic or prophylactic
vaccine indication with a relatively favorable cost of goods expectation in
large scale.

About Aeterna Zentaris

Aeterna Zentaris is an oncology and endocrinology drug development company
currently investigating treatments for various unmet medical needs. The
Company's pipeline encompasses compounds at all stages of development, from
drug discovery through to marketed products. For more information please visit

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the
safe harbour provisions of the U.S. Securities Litigation Reform Act of 1995.
Forward-looking statements involve known and unknown risks and uncertainties
that could cause the Company's actual results to differ materially from those
in the forward-looking statements. Such risks and uncertainties include, among
others, the availability of funds and resources to pursue R&D projects, the
successful and timely completion of clinical studies, the risk that safety and
efficacy data from any of our Phase 3 trials may not coincide with the data
analyses from previously reported Phase 1 and/or Phase 2 clinical trials, the
ability of the Company to take advantage of business opportunities in the
pharmaceutical industry, uncertainties related to the regulatory process and
general changes in economic conditions. Investors should consult the Company's
quarterly and annual filings with the Canadian and U.S. securities commissions
for additional information on risks and uncertainties relating to
forward-looking statements. Investors are cautioned not to rely on these
forward-looking statements. The Company does not undertake to update these
forward-looking statements. We disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any of the
forward-looking statements contained herein to reflect future results, events
or developments, unless required to do so by a governmental authority or by
applicable law.



Investor Relations
Ginette Beaudet Vallières
Investor Relations Coordinator
(418) 652-8525 ext. 265

Media Relations
Paul Burroughs
Director of Communications
(418) 652-8525 ext. 406
Press spacebar to pause and continue. Press esc to stop.